ADDERALL XR(R) - Shire Files Legal Suit Against Barr Laboratories and Impax Laboratories for Infringement of U.S. Patent No. 6,913,768.
PR Newswire Europe, October, 2005
BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, October 20 /PRNewswire/ -- Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that its subsidiary Shire Laboratories Inc. has filed a lawsuit in the U.S. District Court of the Southern District of New York against Barr Laboratories, Inc. ("Barr") and Impax Laboratories, Inc. ("Impax") for infringement of Shire Laboratories U.S. Patent No. 6,913,768 ("'768 Patent").
The lawsuit results from ANDAs (Abbreviated New Drug Applications) filed by Barr and Impax seeking FDA approval to market and sell generic versions of Shire's 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg ADDERALL XR(R) products. The '768 patent issued to Shire on July 5, 2005.
The present case should not...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- LIFO vs. FIFO: a return to the basics
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
